SANUWAVE Health, Inc. Issues Restatement Warning: What Investors Need to Know

SANUWAVE Health, Inc. just dropped a bombshell: its past financial reports are unreliable. This summary cuts through the jargon of their recent 8-K filing, explaining exactly what went wrong, why it's a big deal for investors, and what steps come next.

1. The Core Event: Financial Reports Can No Longer Be Trusted

On March 13, 2026, SANUWAVE Health informed the SEC through an 8-K filing that investors should no longer trust its financial statements from most of 2024 and 2025. This includes quarterly reports (Form 10-Qs) and the full-year 2024 annual report (Form 10-K). The company now admits these reports contain significant errors and must restate them.

To illustrate: Imagine meticulously tracking your personal finances for two years, only to discover you consistently missed a major, recurring bill. All your past budget summaries would be incorrect, forcing you to revise them and realize you owe more than you thought. SANUWAVE now faces this exact scenario with its financial statements.

2. Affected Periods and Disclosure Date

SANUWAVE filed its disclosure on March 13, 2026, using an 8-K. The errors affect financial periods from March 31, 2024, through September 30, 2025. This covers all quarterly reports during that time and the entire fiscal year ending December 31, 2024.

3. The Root Cause: Unaccounted Sales and Use Taxes

The core issue traces back to a long-standing failure to properly handle state sales and use taxes. An outside expert's recent study uncovered that SANUWAVE consistently failed to collect, pay, or set aside funds for these taxes in the various states and local areas where it does business. This wasn't a one-time mistake; it was an ongoing problem that caused the company to understate its financial obligations (liabilities) and overstate its profits in previous reports.

4. Why This Matters: Financial Impact, Trust, and Internal Controls

This serious development carries significant consequences for SANUWAVE and its investors:

• Major Financial Blow: The company expects its financial obligations (liabilities) to jump substantially, by an estimated $4.9 million to $5.2 million as of December 31, 2025. On top of that, it anticipates new expenses—covering taxes, interest, and penalties—totaling $1.6 million to $1.8 million for 2024 and $1.7 million to $1.9 million for 2025. These substantial costs will significantly reduce previously reported earnings and cash flow.
• Damaged Investor Trust: Restatements always erode investor confidence. They signal that the company's past financial performance was misrepresented, leading to doubts about management's reporting accuracy and the company's overall financial health.
• Serious Internal Control Failures: Management is assessing if these errors point to "material weaknesses" in its internal control over financial reporting (ICFR). In plain terms, a material weakness means the company's financial oversight systems are so flawed that there's a good chance significant errors in its financial statements could go undetected or uncorrected. This is a major regulatory red flag, highlighting severe deficiencies in how SANUWAVE manages its finances.

5. Who is Affected?

This restatement will send ripples through several key groups:

• Investors/Shareholders: Your investment faces higher risk and a potential negative impact on the stock price due to the financial corrections and worries about the company's accounting integrity.
• The Company: SANUWAVE will shoulder the financial burden of these obligations and penalties, suffer reputational harm, and must commit substantial resources to fix its accounting systems.
• Management: Leadership will face intense scrutiny to correct the control weaknesses and guarantee accurate financial reporting going forward.
• Auditors: SANUWAVE consulted both its current and former independent auditors (Baker Tilly and Marcum LLP), highlighting the seriousness of these accounting problems.
• Regulators: The SEC will closely watch the restatement process and how the company addresses its internal control issues.

6. What Happens Next: Restatement, Remediation, and Compliance Dangers

Here’s what investors should expect next:

• Immediate Market Reaction: Brace for increased stock price volatility as the market digests this negative news.
• Restatement Filing: The company intends to re-issue the corrected financial statements (Form 10-Qs for 2024 and 2025, and the 2024 Form 10-K) when it submits its annual report for fiscal year 2025 (the "2025 Form 10-K"). While this filing is usually due by March 31, 2026, the restatement makes delays probable.
• Fixing Internal Controls: The 2025 Form 10-K will also outline management's findings on the material weaknesses in ICFR and detail their strategy to correct these flaws. This will likely include putting new tax compliance procedures in place, possibly hiring specialized staff, or bringing in outside tax experts.
• Compliance Dangers: Delays in filing the 2025 Form 10-K could violate NASDAQ listing rules, potentially leading to delisting if SANUWAVE doesn't resolve the issue quickly. There's also the risk of more regulatory oversight or lawsuits from shareholders.

7. Key Takeaways for Investors

If you own or are thinking about investing in SANUWAVE stock, keep these crucial points in mind:

• Negative Financial Impact: The company's financial health was worse than initially reported, with substantial unexpected costs now affecting both past and future earnings.
• Monitor the 2025 Form 10-K Closely: This upcoming filing will reveal the final restated figures, the complete scope of the internal control problems, and management's specific plan to fix them. Pay particular attention to their strategy for preventing future tax non-compliance.
• Evaluate Management's Actions: Assess how effectively and transparently management plans to resolve the core issues and rebuild trust.
• Weigh Long-Term Risks: Beyond the immediate financial setback, consider how these control failures might impact the company's operational efficiency, cost structure, and ability to secure funding in the long run.
• Due Diligence Remains Essential: This situation highlights why thorough research is vital. Always consult official SEC filings for the most precise and comprehensive information.